Pulse Biosciences Bolsters Leadership for Cardiac Ablation Push
Event summary
- Pulse Biosciences appoints Liane Teplitsky as Chief Operating Officer on April 9, 2026.
- Dr. David Kenigsberg transitions to full-time Chief Medical Officer role.
- Teplitsky receives equity inducement awards: 700,000 stock options and 200,000 RSUs.
- Focus on accelerating nPulse Cardiac Catheter Ablation System development.
The big picture
This leadership strengthening positions Pulse Biosciences to prioritize its cardiac ablation technology amid growing competition in electrophysiology. The appointments come as the company seeks to differentiate itself with non-thermal pulsed field ablation, a potentially disruptive approach to treating atrial fibrillation. With Teplitsky's medtech scaling experience and Kenigsberg's clinical trial expertise, the company aims to accelerate both development timelines and regulatory approvals.
What we're watching
- Execution Risk
- How Teplitsky's operational expertise will accelerate cardiac catheter development.
- Regulatory Pathway
- Whether the expanded leadership can expedite IDE pivotal clinical study completion.
- Market Differentiation
- The pace at which nsPFA technology gains adoption in atrial fibrillation treatment.
Related topics